Owners, management and financials
CVR: 43770209
DKK -3,512,912
Gross profit
Net result: DKK -3,936,274
Marigold Innovation ApS (20-24,99%), Thomas B. Poulsen Holding ApS (20-24,99%)
3 more
CVR · view owners
Jan Stenvang
Board: Carsten Grøhn (chair) and 4 members
CVR · view management
Active
Founded 10 January 2023
CVR · view overview
4 employees
CVR · 2026
Director registered: Jan Stenvang
CVR · 19/02/2026
View the full event history
Kripthonite Therapeutics ApS is a Danish company of the type Anpartsselskab based in Aarhus N, founded in 2023. The company is registered under the industry Fremstilling af farmaceutiske præparater. The management consists of Jan Stenvang. The board consists of Carsten Grøhn (chair), Erik Vinther, Kristian Mark Jacobsen and Per Hjerrild. The company's owners include Marigold Innovation ApS, Thomas B. Poulsen Holding ApS and Hjerrild Chemistry Consulting ApS. The company has 4 employees (2026). In 2025, the company reported a gross profit of DKK -3,512,912 and a net result of DKK -3,936,274 compared with DKK -32 the year before. Equity in the 2025 report amounted to DKK 4,598,287.
Selskabets formål er forskning og udvikling af lægemidler og dermed beslægtet virksomhed.
Source: annual reports filed with the Danish Business Authority.
| Period | Gross Profit | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 202501/01/2025 – 31/12/2025 | -3.5M | -3.9M | 4.8M | 4.6M | 1 | |
| 202401/01/2024 – 31/12/2024 | 125K | -32 | 169K | 35K | 1 | |
| 202310/01/2023 – 31/12/2023 | 542K | -5K | 75K | 35K | 1 |
Compared to 129 companies in Fremstilling af farmaceutiske præparater
Comparison is based on industry median values
Screen owners and management against the Danish FSA's official PEP lists
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningThe CVR number of Kripthonite Therapeutics ApS is 43770209.
The owners of Kripthonite Therapeutics ApS include Marigold Innovation ApS, Thomas B. Poulsen Holding ApS and Hjerrild Chemistry Consulting ApS.
The management of Kripthonite Therapeutics ApS consists of Jan Stenvang.
The board of Kripthonite Therapeutics ApS consists of Carsten Grøhn, Erik Vinther and Kristian Mark Jacobsen, with Carsten Grøhn as chair.
In 2025, Kripthonite Therapeutics ApS reported a gross profit of DKK -3,512,912.
Kripthonite Therapeutics ApS had 4 employees in 2026 according to the Danish CVR register.
Claim this page to add your logo and social links. Free to get started.
As of October 14, 2026, Carsten Grøhn has joined the board of directors of Kripthonite Therapeutics ApS.
As of October 14, 2026, Søren Bregenholt Frederiksen has left the board of directors of Kripthonite Therapeutics ApS.
Kripthonite Therapeutics ApS has published its annual report for 2025. Gross profit came to DKK -3,512,912, and the net result was DKK -3,936,274.
As of February 19, 2026, Erik Vinther has joined the board of directors of Kripthonite Therapeutics ApS.
As of February 19, 2026, Peter Horn Møller has left the board of directors of Kripthonite Therapeutics ApS.
As of February 19, 2026, Jan Stenvang is registered as director of Kripthonite Therapeutics ApS.
As of February 19, 2026, Erik Vinther has stepped down as director of Kripthonite Therapeutics ApS.
As of November 1, 2025, Sønderup Godkendt Revisionsaktieselskab has been appointed auditor of Kripthonite Therapeutics ApS.
As of November 1, 2025, Revisionsfirmaet Tom Sønderup I/S has stepped down as auditor of Kripthonite Therapeutics ApS.
As of November 1, 2025, Marigold Maturation Fund K/S is registered as an owner of Kripthonite Therapeutics ApS with an ownership share of 15%.
As of October 1, 2025, Peter Horn Møller has joined the board of directors of Kripthonite Therapeutics ApS.
As of October 1, 2025, Søren Bregenholt Frederiksen has joined the board of directors of Kripthonite Therapeutics ApS.
As of September 30, 2025, Peter Horn Møller has left the board of directors of Kripthonite Therapeutics ApS.
Kripthonite Therapeutics ApS has published its annual report for 2024. Gross profit came to DKK 125,449, and the net result was DKK -32.
As of May 1, 2025, Marigold Innovation ApS is registered as an owner of Kripthonite Therapeutics ApS with an ownership share of 20%.
As of May 1, 2025, Thomas B. Poulsen Holding ApS is registered as an owner of Kripthonite Therapeutics ApS with an ownership share of 20%.
As of May 1, 2025, Hjerrild Chemistry Consulting ApS is registered as an owner of Kripthonite Therapeutics ApS with an ownership share of 20%.
As of May 1, 2025, Jacobsen Biotech ApS is registered as an owner of Kripthonite Therapeutics ApS with an ownership share of 20%.
Kripthonite Therapeutics ApS has published its annual report for 2023. Gross profit came to DKK 541,641, and the net result was DKK -5,407.
As of January 10, 2023, Revisionsfirmaet Tom Sønderup I/S has been appointed auditor of Kripthonite Therapeutics ApS.
As of January 10, 2023, Peter Horn Møller has joined the board of directors of Kripthonite Therapeutics ApS.
As of January 10, 2023, Thomas Bjørnskov Poulsen has joined the board of directors of Kripthonite Therapeutics ApS.
As of January 10, 2023, Kristian Mark Jacobsen has joined the board of directors of Kripthonite Therapeutics ApS.
As of January 10, 2023, Per Hjerrild has joined the board of directors of Kripthonite Therapeutics ApS.
As of January 10, 2023, Erik Vinther is registered as director of Kripthonite Therapeutics ApS.
Kripthonite Therapeutics ApS was founded on January 10, 2023.
Companies in the same industry and area
